Biosynth opens new biological technology facility in China
New biosafety level 2 laboratories to support enzyme development
A new state-of-the-art biological technology facility has opened in Suzhou, China, expanding the global capabilities for critical raw materials production in diagnostics, vaccines, and pharmaceuticals. The facility, operated by Swiss-headquartered Biosynth, is situated within the Lifebay technology park and represents a significant advancement in the company’s Asia-Pacific operations.
Strategic expansion to serve regional markets
The facility’s primary focus will be on supporting the growing demands of in vitro diagnostics (IVD) companies across China, particularly in the areas of infectious diseases, oncology, and autoimmunity. Of particular interest to medical professionals is the planned commissioning of biosafety level 2 laboratories, which will enable the handling and supply of more sophisticated biological diagnostic tools.
According to Chief Commercial Officer Philip Noone, the facility will deliver “comprehensive Biologics, Chemicals, and Complex Peptides” directly to Chinese IVD companies. This marks the first time the company has been able to offer its complete diagnostic solutions portfolio for emerging pathogens in the region.
Laboratory capabilities and research focus
The bio-laboratory complex is designed to enhance internal project development initiatives whilst serving as a distribution hub for the domestic life science market. The facility’s capabilities extend beyond mere distribution, incorporating research and development facilities for enzyme production and development.
General Manager for China, Alessandra Vismara, highlighted the significance of the biosafety level 2 laboratories in the facility’s next phase of development. These laboratories will expand the range of biological diagnostic tools that can be handled and supplied, whilst supporting localised enzyme development and production capabilities.
Supply chain implications
For healthcare providers and researchers, this development represents a strengthening of the life science supply chain in the Asia-Pacific region. The facility’s location in Suzhou’s Wuzhong Economic Development Zone positions it strategically for serving both domestic Chinese markets and broader regional requirements.
Dr Thomas Eisele, Chief Operations Officer, described the facility as a “crucial production site for internal materials” that will also serve as a “distribution and handling hub” for regional customers.
